zeniplatin

01/01/1993 - "Zeniplatin in patients with advanced ovarian cancer, a phase II study with a third generation platinum complex."
01/01/1993 - "Unfortunately, although we have defined definite but modest activity for zeniplatin in platinum-refractory ovarian cancer, further development of this drug has been discontinued because of the severe renal toxicity observed in other clinical trials of this cytotoxic agent."
01/01/1993 - "Phase II trial of zeniplatin (CL 286,558), a new patinum compound, in patients with advanced ovarian cancer previously treated with organoplatinum-based therapy."
01/01/1993 - "25 patients with residual or recurrent ovarian cancer were treated with the new platinum complex zeniplatin (CL 286,558) and 23 patients were evaluable for response. "
01/01/1993 - "A phase II trial of zeniplatin (CL 286,558), a third-generation platinum compound, was conducted in 31 patients with advanced ovarian cancer to examine the safety and activity of the agent when used as a salvage treatment in individuals previously exposed to organoplatinum-based therapy. "

02/01/1995 - "A phase II trial of zeniplatin in metastatic melanoma."
02/01/1995 - "Zeniplatin demonstrated only modest activity in melanoma with significant gastrointestinal and hematologic toxicity."
01/01/1997 - "Zeniplatin in advanced malignant melanoma and renal cancer: phase II studies with unexpected nephrotoxicity."
01/01/1997 - "The results show that zeniplatin has some activity (14%) in patients with advanced malignant melanoma, but no conclusion can be drawn regarding the activity of zeniplatin in renal cancer as the number of patients was too low. "
01/01/1997 - "Zeniplatin gave objective responses in 3 of the 21 evaluable malignant melanoma patients [2 complete responses (CRs) in patients with lymph-node metastases lasted 5 and 14 months, respectively; 1 partial response (PR) in a patient with lymph-node and liver metastases lasted 6 months]. "

01/01/1997 - "Zeniplatin in advanced malignant melanoma and renal cancer: phase II studies with unexpected nephrotoxicity."
01/01/1997 - "The results show that zeniplatin has some activity (14%) in patients with advanced malignant melanoma, but no conclusion can be drawn regarding the activity of zeniplatin in renal cancer as the number of patients was too low. "
01/01/1997 - "The antitumor activity of zeniplatin, a third-generation, water-soluble platinum compound that has shown broad preclinical antitumor activity and no significant nephrotoxicity in phase I trials, was tested in patients with advanced malignant melanoma and advanced renal cancer. "

01/01/1995 - "Zeniplatin, a more water-soluble organoplatinum than cisplatin, was evaluated for clinical pharmacology in the context of a phase II trial in previously treated patients with ovarian carcinoma. "

09/01/1991 - "The most prominent non-hematological side-effect of zeniplatin was nausea and vomiting. "